AQUIPTA: Uses, Dosage & Side Effects

What Is AQUIPTA and What Is It Used For?

AQUIPTA contains the active substance atogepant, a small-molecule antagonist that selectively and competitively binds to the calcitonin gene-related peptide (CGRP) receptor. Unlike monoclonal antibody therapies that target the CGRP ligand itself (such as fremanezumab or galcanezumab), atogepant belongs to the gepant class of medications and acts directly at the receptor level. This receptor-based mechanism of action distinguishes AQUIPTA from other CGRP pathway therapies and allows it to be formulated as an orally bioavailable tablet, providing patients with a convenient, non-injectable treatment option for migraine prevention.

Calcitonin gene-related peptide (CGRP) is a 37-amino acid neuropeptide that has been established as a central mediator in the pathophysiology of migraine. CGRP is widely distributed throughout both the central and peripheral nervous systems, with particularly high concentrations found in the trigeminal ganglion and the perivascular sensory nerve fibers that innervate the cerebral and meningeal blood vessels. During a migraine attack, CGRP is released in substantial quantities from activated trigeminal sensory neurons. This release initiates a cascade of neurobiological events including potent vasodilation of intracranial and meningeal arteries, neurogenic inflammation characterized by plasma protein extravasation and mast cell degranulation, sensitization of both peripheral and central nociceptive (pain-sensing) neurons, and amplification of pain signal transmission through the trigeminal nucleus caudalis to higher brain centers involved in pain perception.

The critical role of CGRP in migraine has been demonstrated through multiple lines of evidence. Intravenous infusion of CGRP in susceptible individuals reliably provokes migraine-like headaches, and elevated CGRP levels have been consistently measured in the jugular venous blood during acute migraine attacks. Furthermore, CGRP levels normalize following effective treatment with triptans, and genetic studies have identified polymorphisms in CGRP-related genes that are associated with increased migraine susceptibility. These findings have established the CGRP pathway as a validated therapeutic target for both acute and preventive migraine treatment.

Atogepant exerts its therapeutic effect by competitively binding to the CGRP receptor with high affinity, preventing the endogenous CGRP ligand from activating the receptor and initiating the downstream signaling cascade that culminates in migraine. The CGRP receptor is a heterodimeric complex consisting of the calcitonin receptor-like receptor (CLR) and receptor activity-modifying protein 1 (RAMP1). Atogepant binds at the interface of this complex, effectively blocking CGRP-mediated signaling. This prevents the vasodilatory, pro-inflammatory, and nociceptive sensitization effects of CGRP, resulting in fewer migraine attacks and reduced headache burden.

AQUIPTA is indicated for the preventive treatment of migraine in adults who experience at least 4 migraine days per month. This encompasses both episodic migraine (defined as fewer than 15 headache days per month) and chronic migraine (defined as 15 or more headache days per month, of which at least 8 are migraine days). The efficacy and safety of atogepant have been established through a robust clinical development program including two pivotal phase III randomized controlled trials:

• ADVANCE (Episodic Migraine): This multicenter, randomized, double-blind, placebo-controlled trial enrolled 910 adults with episodic migraine. Patients were randomized to receive atogepant 10 mg, 30 mg, or 60 mg once daily, or placebo for 12 weeks. All three atogepant doses demonstrated statistically significant reductions in mean monthly migraine days compared with placebo. The 60 mg dose group experienced a mean reduction of 4.2 migraine days per month compared with 2.5 for placebo (p<0.001). The 50% responder rate (proportion of patients achieving at least a 50% reduction in monthly migraine days) was 62% for atogepant 60 mg versus 29% for placebo.
• PROGRESS (Chronic Migraine): This trial enrolled 778 adults with chronic migraine. Patients received atogepant 30 mg twice daily or 60 mg once daily, or placebo for 12 weeks. Both atogepant regimens significantly reduced monthly migraine days compared with placebo. The 60 mg once-daily group experienced a mean reduction of 7.5 migraine days per month versus 5.1 for placebo (p<0.001), representing a meaningful improvement in migraine burden for patients with the most severe form of the disease.

Long-term extension data from studies spanning up to 52 weeks have demonstrated sustained efficacy, with continued reductions in monthly migraine days and improvement in migraine-related disability throughout the treatment period. Patients who responded to treatment maintained their clinical benefit over time, and no tachyphylaxis (loss of treatment effect) was observed. AQUIPTA was first approved by the European Medicines Agency (EMA) in 2024 for migraine prevention. In the United States, atogepant is marketed under the brand name QULIPTA and was approved by the FDA in September 2021 for episodic migraine prevention, with the chronic migraine indication added in March 2023.

What Should You Know Before Taking AQUIPTA?

Contraindications

The primary contraindication to AQUIPTA use is hypersensitivity (allergy) to atogepant or to any of the other ingredients in the formulation. The excipients in AQUIPTA include povidone/vinyl pyrrolidone-vinyl acetate copolymer, tocofersolan (vitamin E polyethylene glycol succinate), mannitol, microcrystalline cellulose, sodium chloride, croscarmellose sodium, colloidal silicon dioxide, and sodium stearyl fumarate. If you have a known allergy to any of these substances, you must not use AQUIPTA.

Post-marketing surveillance and clinical trial data have identified serious hypersensitivity reactions in some patients receiving atogepant. These reactions can include difficulty breathing (dyspnea), swelling of the face, lips, tongue, or throat (angioedema), skin rash, itching (pruritus), and hives (urticaria). Some of these reactions may occur within 24 hours of the first dose, while others have been reported with a delayed onset occurring several days after starting treatment. If you experience signs of a serious allergic reaction after taking AQUIPTA, stop the medication immediately and seek emergency medical attention.

Warnings and Precautions

Before starting AQUIPTA, discuss the following considerations with your healthcare provider:

• Liver disease: AQUIPTA has not been adequately studied in patients with severe hepatic (liver) impairment. Atogepant is partially metabolized by the liver through CYP3A4 pathways. If you have severe liver problems, your doctor may advise against using AQUIPTA or may require additional monitoring. For patients with mild to moderate hepatic impairment, no dose adjustment is generally necessary, but your doctor should be informed.
• Kidney disease: If you have severe kidney problems or are on dialysis, your doctor may prescribe a lower dose of AQUIPTA (10 mg once daily instead of the standard 60 mg). Atogepant is partially cleared through the kidneys, and exposure levels are higher in patients with severe renal impairment. Patients with mild to moderate kidney disease do not typically require dose adjustments.
• History of allergic reactions: If you have experienced serious allergic reactions to other medications, particularly other gepants (CGRP receptor antagonists), inform your doctor before starting AQUIPTA. Cross-reactivity between different gepant medications has not been systematically studied.

Children and Adolescents

AQUIPTA is not recommended for use in children and adolescents under 18 years of age. The safety and efficacy of atogepant have not been established in this age group, and there are currently no clinical data to support its use in pediatric patients. Migraine in children and adolescents may present differently from adult migraine and often requires age-appropriate treatment strategies. If a young person suffers from migraines, healthcare providers should consider evidence-based alternatives that have been studied in the pediatric population.

Pregnancy and Breastfeeding

If you are pregnant, think you may be pregnant, or are planning to become pregnant, consult your doctor before using AQUIPTA. Atogepant should not be taken during pregnancy. The effects of atogepant on human pregnancy have not been adequately studied through controlled clinical trials. Animal reproductive toxicology studies have shown that exposure to atogepant at supratherapeutic doses may be associated with reduced fetal weight. While animal findings do not always predict human outcomes, as a precautionary measure, AQUIPTA should be avoided during pregnancy. Women of childbearing potential should use effective contraception during treatment with AQUIPTA.

It is not known whether atogepant is excreted in human breast milk. Animal studies have shown that atogepant and its metabolites are present in the milk of lactating rats. Because many drugs are excreted in human milk and because of the potential for adverse effects in the breastfed infant, the decision to breastfeed during AQUIPTA treatment should be made in consultation with your doctor. The benefits of breastfeeding for the infant should be weighed against the benefits of AQUIPTA treatment for the mother and any potential risk to the infant.

Driving and Operating Machinery

AQUIPTA may cause somnolence (drowsiness) and fatigue, which are among its commonly reported side effects. If you experience drowsiness or fatigue while taking AQUIPTA, you should exercise caution when driving, operating heavy machinery, or engaging in other activities that require full alertness. Do not drive or operate machinery until you know how AQUIPTA affects you personally. If these side effects are significant, discuss them with your doctor, as they may indicate the need for dose adjustment or timing optimization (for example, taking the medication in the evening).

Important Information About Sodium Content

The sodium content of AQUIPTA varies between tablet strengths. The 10 mg tablets contain less than 1 mmol (23 mg) of sodium per tablet, making them essentially sodium-free. However, the 60 mg tablets contain 31.5 mg of sodium per tablet, equivalent to approximately 1.6% of the WHO-recommended maximum daily sodium intake for adults (2 g per day). This information is particularly relevant for patients on a sodium-restricted diet, such as those with heart failure, hypertension, or kidney disease. If you are monitoring your sodium intake, discuss this with your doctor or pharmacist.

How Does AQUIPTA Interact with Other Drugs?

Unlike CGRP-targeting monoclonal antibodies (such as fremanezumab or galcanezumab), which are degraded through general protein catabolic pathways and have minimal drug interactions, atogepant is a small molecule that is metabolized primarily by hepatic cytochrome P450 3A4 (CYP3A4) enzymes. Additionally, atogepant is a substrate of organic anion-transporting polypeptides OATP1B1 and OATP1B3, as well as P-glycoprotein (P-gp) and breast cancer resistance protein (BCRP) transporters. This metabolic profile means that AQUIPTA has clinically relevant drug interactions that both patients and prescribers must be aware of.

The following table summarizes the key drug interactions with AQUIPTA and the recommended clinical actions:

Major Interactions

Strong CYP3A4 inhibitors represent the most clinically important drug interaction class with AQUIPTA. These medications inhibit the primary enzyme responsible for atogepant metabolism, leading to substantially increased plasma concentrations of atogepant. In pharmacokinetic studies, concomitant administration of ketoconazole (a prototypical strong CYP3A4 inhibitor) with atogepant resulted in approximately a 5.5-fold increase in atogepant area under the curve (AUC). This degree of increase has clear clinical significance and necessitates a dose reduction from the standard 60 mg to 10 mg once daily when AQUIPTA is used with any strong CYP3A4 inhibitor.

Common strong CYP3A4 inhibitors include antifungal agents (ketoconazole, itraconazole, voriconazole, posaconazole), macrolide antibiotics (clarithromycin, telithromycin), HIV protease inhibitors (ritonavir, lopinavir, nelfinavir, indinavir, saquinavir), and certain other medications (nefazodone, cobicistat). If you are prescribed any of these medications while taking AQUIPTA, your doctor must adjust your AQUIPTA dose accordingly.

Strong CYP3A4 inducers such as rifampicin (used for tuberculosis and certain bacterial infections) significantly reduce atogepant plasma levels by accelerating its hepatic metabolism. Pharmacokinetic studies showed that rifampicin reduced atogepant AUC by approximately 60%, which would be expected to substantially diminish the therapeutic efficacy of AQUIPTA. Concomitant use of AQUIPTA with strong CYP3A4 inducers should therefore be avoided. Other strong CYP3A4 inducers include phenytoin, carbamazepine, phenobarbital, and St. John’s Wort (Hypericum perforatum).

OATP inhibitors such as cyclosporine (an immunosuppressant) can increase atogepant exposure by inhibiting the OATP1B1 and OATP1B3 hepatic uptake transporters involved in atogepant disposition. When AQUIPTA must be used with cyclosporine, the dose should be reduced to 10 mg once daily.

Other Considerations

Moderate CYP3A4 inhibitors (such as fluconazole, erythromycin, verapamil, diltiazem, and grapefruit juice) may also increase atogepant exposure to a lesser degree. While routine dose adjustments are not typically required, patients should inform their doctor if they are taking these medications, and clinical monitoring for increased side effects is advisable.

Common medications used by migraine patients, including triptans, NSAIDs (ibuprofen, naproxen), paracetamol (acetaminophen), and oral contraceptives, have not shown clinically significant interactions with atogepant in clinical studies. Atogepant can generally be used alongside these medications without dose adjustment.

What Is the Correct Dosage of AQUIPTA?

AQUIPTA should always be taken exactly as your doctor has prescribed. Do not change your dose or stop taking AQUIPTA without first consulting your doctor or pharmacist. The medication is designed for ongoing daily use as a preventive treatment; it is not intended for the acute (as-needed) treatment of migraine attacks once they have started.

Adults

The standard recommended dose for adults is 60 mg atogepant taken orally once daily. The tablet should be swallowed whole and must not be split, crushed, chewed, or broken before swallowing. AQUIPTA can be taken with or without food, as food does not significantly affect the bioavailability of atogepant. Taking the medication at approximately the same time each day is recommended to maintain consistent blood levels and to help establish a daily routine that supports adherence.

Children and Adolescents

AQUIPTA is not approved for use in patients under 18 years of age. The safety and efficacy of atogepant have not been established in the pediatric population through controlled clinical trials. Migraine in children and adolescents is a significant clinical problem, and ongoing research may eventually provide data to support the use of gepants in younger patients. Until such data are available, healthcare providers should rely on established pediatric migraine treatment guidelines.

Elderly Patients

No dose adjustment is required for elderly patients based on age alone. The clinical development program for atogepant included patients aged 65 years and older, and no clinically meaningful differences in safety or efficacy were observed between older and younger adults. However, elderly patients are more likely to have reduced renal function, to be taking multiple medications (including potential CYP3A4 inhibitors), and to be more sensitive to central nervous system effects such as somnolence. Healthcare providers should consider these factors when prescribing AQUIPTA to older adults and should assess renal function and review the medication list for potential interactions.

Missed Dose

If you miss a dose of AQUIPTA, take it as soon as you remember on the same day. If you have forgotten your dose for an entire day, skip the missed dose and take your next dose as usual the following day. Do not take a double dose (two tablets) to make up for a forgotten dose. Maintaining consistent daily dosing is important for optimal migraine prevention, so consider using a reminder method such as a pill organizer, a smartphone alarm, or taking AQUIPTA alongside another daily routine activity.

Overdose

If you have taken more AQUIPTA than prescribed, contact your doctor, pharmacist, or local poison control center immediately. In clinical development, atogepant was studied at doses higher than the recommended therapeutic dose, and the adverse effects observed were consistent with the known safety profile (primarily gastrointestinal symptoms such as nausea and constipation). There is no specific antidote for atogepant overdose. Treatment should be supportive and symptom-directed. Given that atogepant has a half-life of approximately 11 hours, adverse effects from an acute overdose would be expected to resolve within 2–3 days in most cases.

What Are the Side Effects of AQUIPTA?

Like all medicines, AQUIPTA can cause side effects, although not everyone who takes it will experience them. The side effects described below are based on data from the clinical trial program (including the ADVANCE and PROGRESS pivotal trials and long-term extension studies) as well as post-marketing pharmacovigilance reports. Overall, AQUIPTA has been shown to have a manageable tolerability profile, with the majority of side effects being mild to moderate in severity.

In the pivotal clinical trials, the overall rate of adverse events leading to treatment discontinuation was low (approximately 3–4% across atogepant treatment groups versus 2–3% for placebo), indicating that AQUIPTA is generally well tolerated. The most common reasons for discontinuation were gastrointestinal side effects (nausea and constipation), which typically occurred early in treatment and often improved over time.

Nausea is the most frequently reported side effect with AQUIPTA. In the ADVANCE trial, nausea occurred in approximately 6–12% of patients receiving atogepant (depending on the dose) compared with 5% in the placebo group. In the PROGRESS trial (chronic migraine), the incidence was similar. Nausea tends to be most pronounced during the first few weeks of treatment and often diminishes over time as the body adjusts to the medication. If nausea is bothersome, it may help to take AQUIPTA with food, despite the fact that food is not required for absorption. In clinical practice, taking the medication with a meal or snack is a commonly recommended strategy.

Constipation was reported in approximately 6–7% of patients taking atogepant 60 mg daily in clinical trials versus 1–2% with placebo. This is a known class effect of CGRP pathway-targeting therapies, as CGRP plays a role in gastrointestinal motility. Adequate hydration, dietary fiber intake, and regular physical activity can help mitigate constipation. If constipation persists or becomes severe, your doctor may recommend an over-the-counter stool softener or laxative.

Fatigue and somnolence were each reported in approximately 4–6% of patients in the clinical trials. These effects can affect daily activities, particularly driving and operating machinery. If drowsiness is a concern, consider taking AQUIPTA in the evening before bedtime. This timing may turn the somnolence effect into a therapeutic advantage for patients who also have difficulty sleeping.

Decreased appetite and weight loss were observed in the clinical trial program, with some patients experiencing meaningful reductions in body weight over 12 weeks of treatment. The median weight change was modest (approximately 1–2 kg loss), but individual responses varied. Patients with low body weight or those at risk of malnutrition should be monitored. Conversely, for patients with obesity-related comorbidities, this effect may be considered neutral or potentially beneficial, though AQUIPTA is not approved or recommended as a weight-loss medication.

Elevated liver enzymes (increases in alanine aminotransferase [ALT] or aspartate aminotransferase [AST]) were reported uncommonly in clinical trials. These elevations were generally mild, asymptomatic, and reversible upon drug discontinuation. Severe hepatic injury (e.g., jaundice, hepatic failure) has not been reported. Nevertheless, your doctor may recommend periodic liver function monitoring, particularly during the first months of treatment, and especially if you have pre-existing liver conditions or are taking other potentially hepatotoxic medications.

How Should You Store AQUIPTA?

Proper storage of AQUIPTA ensures the medication maintains its quality, potency, and safety throughout its shelf life. As a small-molecule oral tablet, AQUIPTA has straightforward storage requirements compared with injectable biologic medications, which typically require refrigeration.

Follow these storage guidelines:

• Room temperature storage: AQUIPTA does not require any special storage conditions. Store the tablets at standard room temperature. There is no need for refrigeration.
• Original packaging: Keep the tablets in the original blister packaging until you are ready to take a dose. The blister packaging provides protection from moisture and light, which can degrade pharmaceutical products over time.
• Keep out of reach of children: Store AQUIPTA in a safe, secure location where children cannot access it. Accidental ingestion by a child requires immediate medical attention.
• Expiration date: Do not use AQUIPTA after the expiration date printed on the carton and blister packaging after “EXP.” The expiration date refers to the last day of the stated month. Expired medications may have reduced potency and should be discarded properly.
• Proper disposal: Do not dispose of AQUIPTA tablets in household waste or down the drain. Return unused or expired tablets to your pharmacy for safe disposal in accordance with local environmental protection regulations.

When traveling with AQUIPTA, keep the medication in your hand luggage rather than checked baggage to avoid extreme temperature fluctuations in the aircraft cargo hold. No special temperature-controlled storage is required during travel, which is an advantage over injectable CGRP therapies that may need cold-chain maintenance.

What Does AQUIPTA Contain?

Understanding the complete composition of your medication is important, particularly if you have known allergies, sensitivities, or dietary restrictions related to specific pharmaceutical ingredients. Below is a detailed breakdown of what AQUIPTA tablets contain.

Active Ingredient

The active substance is atogepant, a small-molecule CGRP receptor antagonist belonging to the gepant class. AQUIPTA is available in two tablet strengths:

• AQUIPTA 10 mg: Each tablet contains 10 mg of atogepant. This is a white to off-white, round, biconvex tablet debossed with “A” and “10” on one side.
• AQUIPTA 60 mg: Each tablet contains 60 mg of atogepant. This is a white to off-white, oval, biconvex tablet debossed with “A60” on one side.

Inactive Ingredients (Excipients)

Pack Sizes and Appearance

AQUIPTA tablets are supplied in blister packs. Available pack sizes are 28 tablets (approximately one month’s supply) or 98 tablets (approximately a three-month supply). Not all pack sizes may be marketed in every country.

Marketing Authorization Holder and Manufacturer

AQUIPTA is manufactured by AbbVie S.r.l. (Campoverde di Aprilia, Italy) and marketed by AbbVie Deutschland GmbH & Co. KG (Ludwigshafen, Germany) as the marketing authorization holder for the European market. In the United States, the same active ingredient (atogepant) is marketed under the brand name QULIPTA by AbbVie Inc. AQUIPTA is approved and available in an increasing number of countries worldwide as regulatory approvals continue to be obtained.